All In Biotech

Drug Trial Radar · NCT05683470

Expanded Access RBS2418 Treatment

Expanded Access to RBS2418 for an Individual Patient With Pancreatic Cancer

Last checked: Nov 19, 2026Latest source record: Feb 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

No longer available

Status

No longer available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
Riboscience, LLC.Industry
Sponsor type
Industry
Collaborators
Dr. Bertrand Tuan
First posted
Jan 13, 2023

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
Female only

Summary

As written by the sponsor on the registry.

This is an expanded access treatment protocol designed to provide access of RBS2418 to a single patient with pancreatic cancer.

Conditions

  • Expanded Access in Pancreatic Cancer

Interventions

  • RBS2418Drug

    RBS2418 will be administered orally at 200 mg two times per day (BID).

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.